Excellent assessment from a highly qualified individual.
I think his point about overly high expectations for sales of oral Fanapt immediately after the product launched were especially good. Fanapt didn't "burst onto the scene", it's "crawling onto the scene", but crawl it will.
ROW for oral Fanapt and injectable Fanapt are practically a lock, in my opinion.
I still think this is a good time to get in. I think VNDA will trade in a narrow range for awhile, but if you're an old school "buy and hold" investor, your patience will be rewarded.
corky that was good post. However i stll feel this is a oversold,overshorted VNDA that should have more value presently. You cant take all the value out of a drug in this sector since it just got out the gate, but they have by shorting. Th drug is approved and now selling and available so market is wrong at this price.
kampaa lille, This is what´s it´s all about! Sales!
"Thus, the minimum bar needed for Vanda to break even with current expenses is about $80 million in Fanapt sales per year."
Q1 sales $21M
Q2 sales ?
Q3 sales ?
Q4 sales ?
With Q2 sale below $20M will VNDA not breake even! $20M/$600 per prescriptions = 33333 or 11111/month or 2777 per week. The sale was increasing with just 150 prescriptions per week and I don´t see how they will be able to make $20M at current growth rate!